FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2564451680> ?p ?o ?g. }

• W2564451680 endingPage "e1002199" @default.
• W2564451680 startingPage "e1002199" @default.
• W2564451680 abstract "Circulating tumor DNA (ctDNA) is an approved noninvasive biomarker to test for the presence of EGFR mutations at diagnosis or recurrence of lung cancer. However, studies evaluating ctDNA as a noninvasive real-time biomarker to provide prognostic and predictive information in treatment monitoring have given inconsistent results, mainly due to methodological differences. We have recently validated a next-generation sequencing (NGS) approach to detect ctDNA. Using this new approach, we evaluated the clinical usefulness of ctDNA monitoring in a prospective observational series of patients with non-small cell lung cancer (NSCLC).We recruited 124 patients with newly diagnosed advanced NSCLC for ctDNA monitoring. The primary objective was to analyze the prognostic value of baseline ctDNA on overall survival. ctDNA was assessed by ultra-deep targeted NGS using our dedicated variant caller algorithm. Common mutations were validated by digital PCR. Out of the 109 patients with at least one follow-up marker mutation, plasma samples were contributive at baseline (n = 105), at first evaluation (n = 85), and at tumor progression (n = 66). We found that the presence of ctDNA at baseline was an independent marker of poor prognosis, with a median overall survival of 13.6 versus 21.5 mo (adjusted hazard ratio [HR] 1.82, 95% CI 1.01-3.55, p = 0.045) and a median progression-free survival of 4.9 versus 10.4 mo (adjusted HR 2.14, 95% CI 1.30-3.67, p = 0.002). It was also related to the presence of bone and liver metastasis. At first evaluation (E1) after treatment initiation, residual ctDNA was an early predictor of treatment benefit as judged by best radiological response and progression-free survival. Finally, negative ctDNA at E1 was associated with overall survival independently of Response Evaluation Criteria in Solid Tumors (RECIST) (HR 3.27, 95% CI 1.66-6.40, p < 0.001). Study population heterogeneity, over-representation of EGFR-mutated patients, and heterogeneous treatment types might limit the conclusions of this study, which require future validation in independent populations.In this study of patients with newly diagnosed NSCLC, we found that ctDNA detection using targeted NGS was associated with poor prognosis. The heterogeneity of lung cancer molecular alterations, particularly at time of progression, impairs the ability of individual gene testing to accurately detect ctDNA in unselected patients. Further investigations are needed to evaluate the clinical impact of earlier evaluation times at 1 or 2 wk. Supporting clinical decisions, such as early treatment switching based on ctDNA positivity at first evaluation, will require dedicated interventional studies." @default.
• W2564451680 created "2017-01-06" @default.
• W2564451680 creator A5019097921 @default.
• W2564451680 creator A5022507982 @default.
• W2564451680 creator A5023296573 @default.
• W2564451680 creator A5030246024 @default.
• W2564451680 creator A5036255937 @default.
• W2564451680 creator A5039277233 @default.
• W2564451680 creator A5040195958 @default.
• W2564451680 creator A5058312403 @default.
• W2564451680 creator A5060265115 @default.
• W2564451680 creator A5061180821 @default.
• W2564451680 creator A5069777709 @default.
• W2564451680 creator A5089818289 @default.
• W2564451680 date "2016-12-27" @default.
• W2564451680 modified "2023-10-18" @default.
• W2564451680 title "Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study" @default.
• W2564451680 cites W1546552389 @default.
• W2564451680 cites W1778436402 @default.
• W2564451680 cites W1978285367 @default.
• W2564451680 cites W1983466841 @default.
• W2564451680 cites W1989734503 @default.
• W2564451680 cites W1991581123 @default.
• W2564451680 cites W2013768132 @default.
• W2564451680 cites W2015438948 @default.
• W2564451680 cites W2057707250 @default.
• W2564451680 cites W2070059866 @default.
• W2564451680 cites W2088690692 @default.
• W2564451680 cites W2092479048 @default.
• W2564451680 cites W2097560495 @default.
• W2564451680 cites W2115829250 @default.
• W2564451680 cites W2119048498 @default.
• W2564451680 cites W2119180969 @default.
• W2564451680 cites W2119263822 @default.
• W2564451680 cites W2120869188 @default.
• W2564451680 cites W2121110176 @default.
• W2564451680 cites W2135924719 @default.
• W2564451680 cites W2138713106 @default.
• W2564451680 cites W2140575188 @default.
• W2564451680 cites W2145643405 @default.
• W2564451680 cites W2152241467 @default.
• W2564451680 cites W2152922418 @default.
• W2564451680 cites W2154018281 @default.
• W2564451680 cites W2168420784 @default.
• W2564451680 cites W2198449240 @default.
• W2564451680 cites W2239287815 @default.
• W2564451680 cites W2259143567 @default.
• W2564451680 cites W2292338160 @default.
• W2564451680 cites W2328294134 @default.
• W2564451680 cites W2364794827 @default.
• W2564451680 cites W2520774232 @default.
• W2564451680 cites W2917837889 @default.
• W2564451680 cites W4235642752 @default.
• W2564451680 doi "https://doi.org/10.1371/journal.pmed.1002199" @default.
• W2564451680 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5189949" @default.
• W2564451680 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28027313" @default.
• W2564451680 hasPublicationYear "2016" @default.
• W2564451680 type Work @default.
• W2564451680 sameAs 2564451680 @default.
• W2564451680 citedByCount "72" @default.
• W2564451680 countsByYear W25644516802017 @default.
• W2564451680 countsByYear W25644516802018 @default.
• W2564451680 countsByYear W25644516802019 @default.
• W2564451680 countsByYear W25644516802020 @default.
• W2564451680 countsByYear W25644516802021 @default.
• W2564451680 countsByYear W25644516802022 @default.
• W2564451680 countsByYear W25644516802023 @default.
• W2564451680 crossrefType "journal-article" @default.
• W2564451680 hasAuthorship W2564451680A5019097921 @default.
• W2564451680 hasAuthorship W2564451680A5022507982 @default.
• W2564451680 hasAuthorship W2564451680A5023296573 @default.
• W2564451680 hasAuthorship W2564451680A5030246024 @default.
• W2564451680 hasAuthorship W2564451680A5036255937 @default.
• W2564451680 hasAuthorship W2564451680A5039277233 @default.
• W2564451680 hasAuthorship W2564451680A5040195958 @default.
• W2564451680 hasAuthorship W2564451680A5058312403 @default.
• W2564451680 hasAuthorship W2564451680A5060265115 @default.
• W2564451680 hasAuthorship W2564451680A5061180821 @default.
• W2564451680 hasAuthorship W2564451680A5069777709 @default.
• W2564451680 hasAuthorship W2564451680A5089818289 @default.
• W2564451680 hasBestOaLocation W25644516801 @default.
• W2564451680 hasConcept C104317684 @default.
• W2564451680 hasConcept C121608353 @default.
• W2564451680 hasConcept C126322002 @default.
• W2564451680 hasConcept C143998085 @default.
• W2564451680 hasConcept C188816634 @default.
• W2564451680 hasConcept C207103383 @default.
• W2564451680 hasConcept C2776256026 @default.
• W2564451680 hasConcept C2781197716 @default.
• W2564451680 hasConcept C2781335228 @default.
• W2564451680 hasConcept C44249647 @default.
• W2564451680 hasConcept C48126324 @default.
• W2564451680 hasConcept C49105822 @default.
• W2564451680 hasConcept C50382708 @default.
• W2564451680 hasConcept C55493867 @default.
• W2564451680 hasConcept C71924100 @default.
• W2564451680 hasConcept C86803240 @default.
• W2564451680 hasConceptScore W2564451680C104317684 @default.

• next